A House committee investigating the safety and effectiveness of the popular cholesterol drug Vytorin and one of its components is turning up the heat on the drug's makers.
U.S. stock futures rebounded Friday following a better-than-expected July employment report and even as General Motors booked a nearly $16 billion loss.
Stocks closed modestly lower Monday, as rising oil prices and concerns in the tech and drug sectors overpowered a better-than-expected earnings report from Bank of America.
Stock futures climbed Monday morning as investors cheered better-than-expected earnings from Bank of America and the announcement of a deal between Yahoo and activist investor Carl Icahn.
Stocks inched higher Thursday, as investors continued to bet that the worst of the credit crisis is behind the market. However, gains were limited by some jitters ahead of Friday's big monthly jobs report.
Falling oil prices helped lift stocks Monday, at the end of an otherwise abysmal quarter on Wall Street, marred by fears of a recession amid the housing crisis and credit market fallout.
Democrats have long served as the traditional enemy of Big Pharma, but in this presidential campaign, the left is taking the lion's share of drugmaker money.
Is low cholesterol the pathway to a healthier heart? That's certainly what most medical experts - and their patients - have assumed for the last 30 years or so. But a recently-released study of Merck and Schering-Plough's cholesterol-lowering drug, Vytorin, is giving new voice to medical critics who have groused for decades about the questionable benefit of using medications to lower cholesterol and thereby prevent heart disease.
Surprising study results show that the popular heart drug doesn't live up to its claims -- and three new trials are now under way
Tech stocks held on to gains Monday afternoon, near the end of a choppy session, but the broader market was mixed as investors remained wary after last week's big selloff.
A House committee investigating the safety and effectiveness of the popular cholesterol drug Vytorin and one of its components is turning up the heat on the drug's makers.
U.S. stock futures rebounded Friday following a better-than-expected July employment report and even as General Motors booked a nearly $16 billion loss.
Stocks closed modestly lower Monday, as rising oil prices and concerns in the tech and drug sectors overpowered a better-than-expected earnings report from Bank of America.
Stock futures climbed Monday morning as investors cheered better-than-expected earnings from Bank of America and the announcement of a deal between Yahoo and activist investor Carl Icahn.
Stocks inched higher Thursday, as investors continued to bet that the worst of the credit crisis is behind the market. However, gains were limited by some jitters ahead of Friday's big monthly jobs report.
Falling oil prices helped lift stocks Monday, at the end of an otherwise abysmal quarter on Wall Street, marred by fears of a recession amid the housing crisis and credit market fallout.
Democrats have long served as the traditional enemy of Big Pharma, but in this presidential campaign, the left is taking the lion's share of drugmaker money.
Is low cholesterol the pathway to a healthier heart? That's certainly what most medical experts - and their patients - have assumed for the last 30 years or so. But a recently-released study of Merck and Schering-Plough's cholesterol-lowering drug, Vytorin, is giving new voice to medical critics who have groused for decades about the questionable benefit of using medications to lower cholesterol and thereby prevent heart disease.
Surprising study results show that the popular heart drug doesn't live up to its claims -- and three new trials are now under way
Tech stocks held on to gains Monday afternoon, near the end of a choppy session, but the broader market was mixed as investors remained wary after last week's big selloff.
Technology shares bounced Monday, helping the broader market erase losses, as investors tiptoed back into stocks after last week's big selloff.
U.S. stocks slipped at the start of trading Monday amid continuing concerns about the economy, corporate earnings and the price of oil.
The Securities and Exchange Commission has asked the top brass of nearly 300 U.S. companies to better explain the pay packages of top executives, according to a report Friday.
Sharing is not something most scientists do well. It makes sense. In the laboratory, valuable intellectual property flows from each new discovery. It's the coin of the realm, and as such researchers guard it closely.
Schering-Plough Corp. said Monday that second-quarter earnings rose sharply, fueled by growing demand for its Zetia and Vytorin cholesterol drugs and treatments for arthritis and allergies.
Stocks got off to a higher start Monday, helped by some surprisingly strong earnings from Dow component Merck and some dealmaking activity.
Are you scared yet? After enjoying records for the Dow and the S&P throughout the spring, investors have faced some rough selloffs in June.
A cure for lower back pain could be the next big business idea - at least that's what a panel of judges thought when they picked the winner of the University of Pennsylvania Wharton School's business plan competition Tuesday.
The following are some of Thursday's most actively traded stocks:
It's hard out there for drug sales reps--particularly if they work in places where gaining access to doctors is becoming increasingly difficult.
As Big Pharma faces patent expirations on some of its most lucrative drugs, the industry is trying to reinvigorate sales by finding creative ways to land new patents - but on the same old drugs.
The following shares were among the most actively traded Friday:
The following shares were among the most actively traded Monday:
Stocks struggled for direction Monday morning as investors weighed a rash of merger and acquisition news with the latest worries about the subprime mortgage lenders.
Stocks were choppy Monday morning as lower oil prices and some merger news vied with ongoing worries about the subprime mortgage lenders and some investor reluctance after last week's advance.
U.S. stocks were little changed at Monday's open as concerns about the financial sector in the wake of the latest New Century news overshadowed a slew of deals.
STOCKHOLM -(Dow Jones)- Danish vaccine manufacturer ALK-Abello A/S (ALK-B.KO) said Wednesday it has signed a deal with Schering-Plough Corp. (SGP) of the U.S. to develop its tablet-based allergy vaccines for North America, sending shares up as much as 17% in early trading.
Novartis could be the hottest drug giant in 2007, analysts say, with Schering-Plough and Eli Lilly & Co. not far behind.
Carrie Cox, the 49-year-old EVP; President, Global Pharmaceuticals of Schering-Plough, ranks No. 39 on Fortune's 2006 list of 50 Most Powerful Women.
The drug giant Schering-Plough is seriously considering approaching Bristol-Myers with a merger offer, according to a news report.
Schering-Plough said Tuesday it settled a criminal investigation into its sales practices and agreed to pay $435 million in fines and damages.
Drugmaker Schering-Plough may have wowed investors with strong second-quarter earnings - but the company has a cholesterol problem.
Stocks jumped at the open Monday, with a pair of big mergers and a pullback in oil prices inspiring investors to scoop up beaten-down shares after last week's pummeling.
Big Pharma is feeling the squeeze as name-brand drugs go off patent, which is why analysts are expecting a flat or modest second quarter for most of the biggest U.S. drug makers.
The Supreme Court Monday agreed to consider an appeal by the largest U.S. telephone carriers seeking the dismissal of a class-action antitrust suit against them.
Pfizer and Schering-Plough could easily snap up the smaller drugmaker Sepracor but industry analysts say risks to its two products would limit any potential gains.
Merck and Schering-Plough announced a study on Sunday showing that their combination drug Vytorin is better at lowering cholesterol than competing drug Crestor from AstraZeneca.
Allergy season is in full swing and, in the $25 billion market for respiratory drugs, GlaxoSmithKline is likely to hold its throne as the asthma king for this season and years to come, despite growing competition.
Now that the nation's big drugmakers have reported mostly strong first-quarter results, how do things look going forward?
Schering-Plough ranks no. 250 on this year's list of the FORTUNE 500, with $9,508 million in revenues, up 14.9% from the previous year. The Kenilworth, N.J.-based company was ranked no. 264 on the 2005 list. Its 2005 profits were $269 million.
Big drugmakers put up mostly strong earnings this week, triggering a variety of reactions on the stock market and a mixed bag of analyst expectations for the year.
Schering-Plough, once the troubled child of the drug industry, is making a comeback with a hot new drug.
Falling oil prices and strong earnings from the drugmaker were among the factors boosting stocks Monday morning.
Three drugmakers are among the companies named to an annual list of the top 10 family-friendly employers unveiled Monday.
Vytorin, a relatively new cholesterol-blocking drug from Merck and Schering-Plough, has outpaced sales of a blockbuster rival, according to a report Monday from Friedman, Billings, Ramsey & Co.
If you're hoping for some good results from the drug sector this week, take an aspirin. With two exceptions, the Street expects the earnings pain among drug makers to continue.
Drugmakers rue the day when patents expire on blockbuster products, but some companies have found ways to relieve the pain of patent loss and wring more sales out of name brands.
Wal-Mart, the number one retailer, will place all over-the-counter cold medicines containing a key ingredient used in the manufacture of illegal drugs behind the pharmacy counter, a company spokeswoman said Tuesday.
Albertson's Inc., the food and drug retailer, announced Monday that certain over-the-counter cold medicines will now be sold from behind the pharmacy counter, because the key ingredient is used to manufacture illegal drugs.
People for the Ethical Treatment of Animals (PETA), citing recent Securities and Exchange Commission rulings, said Wednesday that the boards of General Electric and two other companies must allow shareholders to vote on resolutions seeking to replace "painful and deadly" animal testing with more humane alternatives.
Talk about a great way to kick off a meeting.
The earnings parade continued after the closing bell Thursday as Electronic Data Systems, John Hancock and Maxim Integrated Products all reported quarterly results.
Are the "big pharmas" finally ready to move up from the back of the pack?
U.S. stocks were mixed early Monday as investors geared up for quarterly earnings reports from roughly 30 percent of the Standard & Poor's 500 due this week.
U.S. stocks, fresh off their first losing week of 2004, will be subject to more corporate quarterly results and the December existing home sales figures as the investing week starts Monday.
In an industry characterized by change, Samuel Isaly has been a rare constant.
In an industry characterized by change, Samuel Isaly has been a rare constant. Since becoming a drug analyst at age 23, after graduating from the London School of Economics, the manager of the $2 ...
With heart and lung surgeon Bill Frist as the Senate's new majority leader, medical matters will get a lot of attention in Washington--especially a prescription-drug benefit as part of Medicare. Pr...
Springtime on the plains of Midland, Texas, is an asthmatic's nightmare. Along with the tumbleweed and dust, there's always too much pollen floating in the wind. Alexis Milmine feels a stirring in ...
TALK ABOUT A HIDDEN GEM. Pelican's managers don't court media attention. But this small fund (only $117 million in assets) has been quietly beating the pants off the competition for the past 10 yea...
Even through stock market jolts, the merger-and-acquisition frenzy continues unabated. As CEOs struggle to keep pace with changing technology, it gets harder to predict what they'll do. Previously ...
STOCKS Bunzl (distributor of packaging material), Iberdrola (Spanish utility), Yalplay (Internet music company), Schering-Plough, Tachihi Enterprise (Japanese real estate manager), Vivendi (French ...
Size of revenues is the measure we use to rank the FORTUNE 500, but it's not the only one that counts. That's why we also rate the 500 on 12 other performance criteria. Spinoffs and mergers account...
STOCKS
How does A.G. Edwards outdistance the S&P 500--and many bigger rivals? Stuart Freeman, the strategist who oversees Edwards' focus list, says the firm's St. Louis location probably helps: "We're les...
Crystal Johnson had never heard of Florida A&M University when a phone call from its president, Frederick Humphries, roused her early one morning four years ago. A National Achievement Scholar from...
It's a blood-borne disease, transmitted through transfusions, sex, and shared needles. And it's a silent disease; people can go years before developing any symptoms.
It's been a rough ride for investors in growth stocks this year. While some of the best, like Wal-Mart Stores, Philip Morris, and Coca-Cola, are still within points of their highs, the rest have be...
When money managers recommend a stock, it's comforting to know that they own the shares themselves. But with the Dow at near-record heights and consumer confidence at a near-record low, I've been a...
In 1985, when the dollar began its downhill schuss against foreign currencies, falling nearly 50%, stocks in leading export companies moved sharply upward (see the chart below). Reason: as goods pr...
It's one of the Great Dumb Annual Rites of American Business, observers of the corporate scene, and it will soon be upon us. Call it the psychic slaughter of the innocents, the ruin of youth, or to...
Though they welcomed the general prospect of a weaker dollar with a brief cheer -- the Dow Jones industrial average rose more than 18 points the day after the Plaza Hotel announcement -- investors ...
BIOTECHNOLOGY still generates more headlines than profits, and no major drug company knows that better than Schering-Plough. It made one of the earliest and costliest bets on the science -- and has...
CANCER is no longer a taboo subject at advertising agencies. Well before President Reagan's operation for cancer of the colon, Kellogg Co., the U.S. cereal king (1984 sales: $2.6 billion), launched...
Hoffman-La Roche said it was granted the first U.S. patent for a type of interferon that has been tested for treatment of cancer and as a prevention against the common cold. The New Jersey-based he...
| Most Viewed | Most Emailed | Top Searches |
| Most Viewed | Most Emailed | Top Searches |
Video
